ASCO 2021 | Transfusion-independence associated with OS in SIMPLIFY-1 and SIMPLFY-2
Ruben Mesa
• 28 May 2021
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the findings of an analysis of long-term outcomes of the SIMPLIFY-1 (NCT01969838) and SIMPLIFY-2 (NCT02101268) studies. Prof. Mesa reports that transfusion independence was associated with overall survival (OS) in patients receiving momelotinib, and comments on the impact on spleen symptoms and anemia. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
